Carl Weissman

Carl Weissman is the acting CEO of OSS Healthcare, a joint venture between MPM Capital and the oncology division of Novartis. Prior to joining OSS in 2014, Carl served as Chairman and CEO, and then as a Senior Advisor, of Accelerator, a joint investment vehicle backed by a syndicate of venture capital firms and co-founded by MPM Capital. Accelerator invests in and actively manages emerging biotechnology companies, and in his capacity as CEO there Carl formed and managed twelve companies over the span of a decade. Carl also served as a Managing Director at OVP Venture Partners from 2009-2012 where he focused on the digital biology sector. He served on the Board of Directors for Allozyne, Accelerator (and all twelve companies formed and managed by Accelerator), Novomer, Viral Logic Systems Technology (VLST) and Fate, and was a Board Observer to CODA Genomics and NanoString. Carl was previously a Venture Partner at MPM Capital from 2001-2008. During that time, he served as President and CEO of an MPM human genetics portfolio company called Centagenetix from 2001-2003. Carl led the 2003 merger of Centagenetix with Elixir Pharmaceuticals, catalyzing a $40M Series B financing in the combined company, and remained on the board of the combined company through 2005. Prior to joining MPM as a Venture Partner, he spent six years at Prolinx, Inc., where he held a number of positions, culminating as the head of both Finance and Business Development. Carl serves on the board of Matrix Genetics.